Upperton Pharma Solutions
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA
UNITED KINGDOM
E: contact@upperton.com
W: upperton.com
LinkedIn: https://www.linkedin.com/company/upperton/

COMPANY DESCRIPTION

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.

With over 25 years of experience, Upperton excels in rapid product introductions.

Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies.

We are flexible and nimble, enabling rapid decision-making, problem-solving, collaboration, and product introduction within 4-6 weeks.

With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise covers all layers of our operations.

For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.

Integrated CDMO Services

• Formulation Development
• Phase 1, 2 & 3 Clinical Supply
• Process Scale-Up & Optimisation
• Registration Activities
• Analytical Development & Validation

Experts in Oral, Nasal, Pulmonary & Sterile Dosage Forms

Upperton offers expertise in developing a range of small molecule and biologics dosage forms, providing support from early feasibility studies through to clinical and commercial manufacture.

Oral Solids: Upperton specialises in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets (IR, MR, SR, Minitabs)

Nasal: Supporting both liquid and dry powder formulation, the development platform, UpperNose™, streamlines and accelerates the process of developing nasal dosage forms for clinical trial studies.

Pulmonary: Through expertise in formulation development, particle engineering and device selection. Upperton offers both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery into the lungs.

Sterile: Our team can support you with aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.

Our Manufacturing Capabilities at a Glance

• Up to 1,000,000 tableting capacity per day
• 500g-205kg blending capacity
• Up to 2,000 blister packaging units per day
• Up to 50kg tablet coating per batch
• Up to 350,000 capsule filling (powder) capacity per day
• Up to 1000kg dry granulation capacity per day
• 0.5g-10kg spray drying batch sizes (aqueous and solvent)
• 20 litres solution preparation vessels capacity with overhead mixing
• 10 state-of-the-art GMP manufacturing suites

Our Approach to Project Delivery

Upperton tailors projects to fit specific client timelines and requirements, prioritizing effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.

Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, QA, and technical transfer. The inclusion of an Executive Leadership Team member in every project, ensures that decisions are made under expert guidance.

Resources

The New Rules of CDMO Partnerships: What Biotechs Should Be Looking for Next

Pharmaceutical Spray Drying: Technology & Applications 

Transitioning Your Product from Phase 1 To Phase 2 Clinical Studies 

Nose To Brain (N2B) Drug Delivery – Benefits & Challenges 

Nasal Delivery of Spray Dried Biologics: Opportunities & Challenges 

Tackling Poor Bioavailability with Early Formulation Strategies